[go: up one dir, main page]

WO2008083157A3 - Altering pgc-1alapha, ampk, fiaf, or the gastrointestinal microbiota as a means to modulate body fat and/or weight loss in a subject - Google Patents

Altering pgc-1alapha, ampk, fiaf, or the gastrointestinal microbiota as a means to modulate body fat and/or weight loss in a subject Download PDF

Info

Publication number
WO2008083157A3
WO2008083157A3 PCT/US2007/088822 US2007088822W WO2008083157A3 WO 2008083157 A3 WO2008083157 A3 WO 2008083157A3 US 2007088822 W US2007088822 W US 2007088822W WO 2008083157 A3 WO2008083157 A3 WO 2008083157A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
pgc
altering
ampk
fiaf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/088822
Other languages
French (fr)
Other versions
WO2008083157A2 (en
Inventor
Jeffrey Gordon
Fredrik Backhed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Louis University
Washington University in St Louis WUSTL
Original Assignee
St Louis University
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Louis University, Washington University in St Louis WUSTL filed Critical St Louis University
Publication of WO2008083157A2 publication Critical patent/WO2008083157A2/en
Publication of WO2008083157A3 publication Critical patent/WO2008083157A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides compositions and methods to modulate body fat and/or weightloss in a subject by altering either the amount of or the activity of a Pgc-1a polypeptide, an AMPK polypeptide, a Fiaf polypeptide, or a combination thereof, in the subject.
PCT/US2007/088822 2006-12-29 2007-12-26 Altering pgc-1alapha, ampk, fiaf, or the gastrointestinal microbiota as a means to modulate body fat and/or weight loss in a subject Ceased WO2008083157A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88269006P 2006-12-29 2006-12-29
US60/882,690 2006-12-29

Publications (2)

Publication Number Publication Date
WO2008083157A2 WO2008083157A2 (en) 2008-07-10
WO2008083157A3 true WO2008083157A3 (en) 2008-10-16

Family

ID=39589193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/088822 Ceased WO2008083157A2 (en) 2006-12-29 2007-12-26 Altering pgc-1alapha, ampk, fiaf, or the gastrointestinal microbiota as a means to modulate body fat and/or weight loss in a subject

Country Status (1)

Country Link
WO (1) WO2008083157A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120027737A1 (en) 2009-03-25 2012-02-02 Chr-Hansen A/S Use of probiotics to ameliorate diet-induced insulin resistance
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
PL3628161T3 (en) 2012-11-23 2023-08-07 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP3904502A3 (en) 2013-02-04 2022-02-23 Seres Therapeutics, Inc. Compositions and methods
HK1219022A1 (en) 2013-02-04 2017-03-24 Seres Therapeutics, Inc. Methods of populating a gastrointestinal tract
US10076546B2 (en) 2013-03-15 2018-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2015077794A1 (en) 2013-11-25 2015-05-28 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP3082431A4 (en) * 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
EP3193901B1 (en) 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
LT3065748T (en) 2014-12-23 2018-03-12 4D Pharma Research Limited A bacteroides thetaiotaomicron strain and its use in reducing inflammation
SMT202200174T1 (en) 2015-06-15 2022-05-12 4D Pharma Res Limited Compositions comprising bacterial strains
SG10201912323VA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
PL3307288T3 (en) 2015-06-15 2019-12-31 4D Pharma Research Limited Compositions comprising bacterial strains
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
HK1254843B (en) 2015-11-20 2020-04-17 希杰生物科技株式会社 Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP3520801A1 (en) 2016-03-04 2019-08-07 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
TWI802545B (en) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 Compositions comprising bacterial strains
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
JP7212945B2 (en) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド Compositions containing bacterial strains
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
TWI767013B (en) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 Compositions comprising bacterial strains
MA49425A (en) 2017-06-14 2020-04-22 4D Pharma Res Ltd COMPOSITIONS CONTAINING BACTERIAL STRAINS
MA49373B1 (en) 2017-06-14 2021-02-26 4D Pharma Res Ltd Compositions comprising bacterial strains
CA3072206A1 (en) 2017-08-14 2019-02-21 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
BR112020008552A2 (en) 2017-10-30 2020-12-29 Seres Therapeutics, Inc. methods and compositions for treating antibiotic resistance

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113889A1 (en) * 2001-05-21 2003-06-19 Millennium Pharmaceuticals, Inc. FARS1, a human secreted protein and uses thereof
US20050038068A1 (en) * 2003-05-16 2005-02-17 Iyengar Rajesh R. Thienopyridones as AMPK activators for the treatment of diabetes and obesity
US20050239706A1 (en) * 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113889A1 (en) * 2001-05-21 2003-06-19 Millennium Pharmaceuticals, Inc. FARS1, a human secreted protein and uses thereof
US20050038068A1 (en) * 2003-05-16 2005-02-17 Iyengar Rajesh R. Thienopyridones as AMPK activators for the treatment of diabetes and obesity
US20050239706A1 (en) * 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KERSTEN ET AL.: "Characterization of the Fasting-induced Adipose Factor FIAF, a Novel Peroxisome Proliferator-activated Receptor Target Gene .", THE JOURNAL OF BIOLOGICAL CHEMISTRY ., vol. 275, no. 37, 15 September 2000 (2000-09-15), pages 28488 - 28493, XP002217322 *

Also Published As

Publication number Publication date
WO2008083157A2 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
WO2008083157A3 (en) Altering pgc-1alapha, ampk, fiaf, or the gastrointestinal microbiota as a means to modulate body fat and/or weight loss in a subject
WO2008053444A3 (en) Treating a respiratory condition with bifidobacterium
WO2011073437A3 (en) Bacteriocin- and prebiotic-based cosmetic or dermatological compositions
WO2009074735A3 (en) Use of a novel natural agent in cosmetic compositions
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2010069532A8 (en) Antibodies against human angiopoietin 2
WO2008085221A3 (en) Therapeutic use of cd31 expressing cells
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2006096614A3 (en) Angiogenic heparin binding peptide amphiphiles
WO2012075407A3 (en) Blood collection devices containing blood stabilization agent
LT2821494T (en) Compositions and methods for the biosynthesis of 1,4-butanediol and its precursors
NZ588111A (en) Composition comprising a N-cyanomethyl-4-trifluoromethyl-3-pyridinecarboxyamide or its salt and a potency-enhancing component, and its use to control pests
WO2008034013A3 (en) Medical devices and methods of making the same
WO2009101503A3 (en) Use of natural active substances in cosmetic or therapeutic compositions
IL198411A0 (en) Haloalkylsulfonanilide derivative or salt thereof, herbicide comprising the derivative as active ingredient, and use of the herbicide
WO2012051318A8 (en) Sulphonamide compounds and methods of making and using same
WO2009085889A3 (en) Compositions and methods for reducing or preventing water loss from the skin
WO2007084857A3 (en) Methods and compositions for treating cell proliferative disorders
WO2008089022A3 (en) Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
EP2180024A4 (en) Hydrophilic film-forming composition, spray composition, and hydrophilic member using the same
WO2010046061A3 (en) Cosmetic and/or pharmaceutical formulations
WO2008135819A8 (en) Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenylhexanamide
WO2007106915A8 (en) Antibodies to egfl7 and methods for their use
WO2009044363A3 (en) A composition for applying to keratinous materials, the composition including a holographic pigment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07869906

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07869906

Country of ref document: EP

Kind code of ref document: A2